{"success":true,"data":{"pressRelease":{"id":"111485","rtpr_id":"nGNX9Y9Clg","ticker":"SILO","exchange":"NASDAQ","all_tickers":["SILO"],"title":"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform ","author":"Globe Newswire","published_at":"2026-08-06T12:50:00.098Z","article_body":"Collaboration supports development of a next-generation AWS-native platform\ndesigned to accelerate commercialization, scalability and enterprise adoption\n\nSARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO)\n(“Silo” or “the Company”), a managed AI agent platform and\ndevelopmental-stage biopharmaceutical company focused on novel therapeutics\nand drug delivery systems, today announced that its wholly owned subsidiary,\nQwikAgents, has engaged Caylent, a cloud services company and Amazon Web\nServices (AWS) Premier Tier Services Partner, to design and build an\nAWS-native QwikAgents platform.\n\nThe collaboration represents the next phase in the evolution of the QwikAgents\nplatform. Rather than migrating the existing application, Caylent will build a\nnew AWS-native foundation that preserves QwikAgents' core functionality while\nenhancing scalability, performance and security for enterprise deployment and\nfuture product innovation. The engagement is also structured to align with AWS\nfunding programs, with funding support expected from AWS and Caylent.\n\n“This collaboration is an important step in positioning QwikAgents for\nenterprise growth,” said Eric Weisblum, Chief Executive Officer of Silo\nPharma. “By combining our AI platform with Caylent's AWS expertise, we're\ncreating a scalable foundation to accelerate commercialization and future\ninnovation.”\n\nThe AWS-native platform is expected to enhance the scalability, performance\nand security of QwikAgents while accelerating future product development and\nsupporting the platform's long-term commercialization strategy.\n\nAbout Silo Pharma, Inc.\n\nQwikAgents, Silo Pharma's wholly owned artificial intelligence subsidiary, is\na managed AI agent platform that delivers dedicated autonomous agents for\nresearch, content generation, scheduling, and workflow automation — each\nrunning in a persistent environment with proprietary smart-routing across\nmultiple AI models. The subsidiary reflects Silo's strategy to expand into\nhigh-growth technology markets while continuing to advance its core\nbiopharmaceutical pipeline. qwikagents.com\n(https://www.globenewswire.com/Tracker?data=9K6NS4ihN_hVXTaR6lpDPDIj4TmCtZJRVcSGtMw7Ap4CHfXbmUGhbiYMycFQ61z2SxtHgjCaJ_zEx0tVitPYLq3BSAsKdnEKUUXygOnkexCL7JXSBF2mHY7SCuBl3SQxlKq7gR-wel1hMlWchCwgYU9HU9CuzSiAaqQcnadbksKMGm5ENoDbqppWOTvzz5tlDPiC-HpPCBd_v6E2MI6YW5qv_2GPR-ccFocmYJuXskQ=)\n\nSilo Pharma is a diversified developmental-stage biopharmaceutical company\nwith a therapeutic focus on addressing underserved conditions, including\nstress-induced psychiatric disorders, chronic pain, and central nervous system\n(CNS) diseases. The Company’s portfolio includes innovative programs such as\nSPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and\nchronic pain, and a preclinical asset targeting Alzheimer’s disease.\nSilo’s research is conducted in collaboration with leading universities and\nlaboratories. silopharma.com\n(https://www.globenewswire.com/Tracker?data=SNm6qf9BFWv-jBQKKGlrtpSMZWwn-66SI4xErF1TQmGmcYT6HtnIzYfAUfsE50-2PLB2xAZfdHi1TvurO4MVV2NcrxAsAoHWtEUPiq6WEU-Q1U8cflSq3_ssxqgIQok1yfA0fkcg9_1wSaViRbpsm5CWKDH2HBI7k-DvtgA4cBnPJRZcsXMrOUj7aazp1I8yIEsieb0kP-gEajJSzVae8Z13AGPbHoPToIFoBy_xsqKzfKZ4a0cGIzZBQh21ZqiFFM2NHY6nAumu8lNMWR3ErtcO4g9HxBrI4aNpZfsKfnPUeRcvKnJ4hmRn9WQCn7LdnLf7xd_bm8pyKjEjE_LEz1MVIcRZsjkYsDbrOPlkH5G-jraO4NE92iEuo_QJOU5h76WNS6sqoEkQ0mKB2QzI4NCGVqoXygXQmIZTl-vSGZ46p7lrRB6pbgWJBqpTN2_mu3MH__6h0IidZR3lhGqsmj9JXasPdFY-_FPeIEfUPnJSG8EDvyASA3QFmTbu5KRBffjFDWzXfS158impgF3zO9yI-3hkLaxGyWpRVM70bX9sLrxypKOrlezTVugWlDklKQjAC53m8SHQjzlKG8c9D86IR-yyzA7gLN23adkSG_GyR9tsgw9f04qxsR0EqoV_MyNvuj3h61i3bq3EHFHllwBmc-Y5WuWtC_damJ9MYLwwFV4usw23VQkmgUFb0Rnpz3YKwB9kybLQE0m1xEhet-WvkuGTgVbxHO6dFYUiWKP0RyOuRjzoSOyuD_abB368S5VAx5Vo29XQGFAbVMDgXQLPdYfVmOeLjOpmVyAKbweP6n6tUKHngI6T6y65PyXQnOheJHLn9a98MwhBKbm4341GOZdOSYrzH-mBnTqO49BuoetwngXre0TTXUK3d_JDNCCny-IhateG4T4zkfodV_XZ7H6zba9dgkFoFJdQLrVsE4gyqW_fDZngUSANoQyAHr3Y8_9uAt7d2MnHXA9LfJZxpP-ho-d_jzj9oz5frk_DYCX6QWIIkcF_ZN501_ld)\n\nForward Looking Statements\nThis news release contains “forward-looking statements” within the meaning\nof the “safe harbor” provisions of the Private Securities Litigation\nReform Act of 1995. These statements are identified using words “could”,\n“believe”, “anticipate”, “intend”, “estimate”, “expect”,\n“may”, “continue”, “predict”, “potential”, and similar\nexpressions that are intended to identify forward-looking statements. Such\nstatements involve known and unknown risks, uncertainties, and other factors\nthat could cause the actual results of the Company to differ materially from\nthe results expressed or implied by such statements, including statements\nabout changes to anticipated sources of revenues, future economic and\ncompetitive conditions, difficulties in developing the Company’s technology\nplatforms, retaining and expanding the Company’s customer base, fluctuations\nin consumer spending on the Company’s products and other factors.\nAccordingly, although the Company believes that the expectations reflected in\nsuch forward-looking statements are reasonable, there can be no assurance that\nsuch expectations will prove to be correct. The Company disclaims any\nobligations to publicly update or release any revisions to the forward-looking\ninformation contained in this press release, whether as a result of new\ninformation, future events, or otherwise, after the date of this press release\nor to reflect the occurrence of unanticipated events except as required by\nlaw.\n\nContact\n\n(800) 705-0120\ninvestors@silopharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/3b635464-4382-4b8b-8175-39cc32e08050)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9Y9Clg","title":"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform ","author":"Globe Newswire","ticker":"SILO","created":"2026-08-06T12:50:00.098Z","tickers":["SILO"],"exchange":"NASDAQ","article_body":"Collaboration supports development of a next-generation AWS-native platform\ndesigned to accelerate commercialization, scalability and enterprise adoption\n\nSARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO)\n(“Silo” or “the Company”), a managed AI agent platform and\ndevelopmental-stage biopharmaceutical company focused on novel therapeutics\nand drug delivery systems, today announced that its wholly owned subsidiary,\nQwikAgents, has engaged Caylent, a cloud services company and Amazon Web\nServices (AWS) Premier Tier Services Partner, to design and build an\nAWS-native QwikAgents platform.\n\nThe collaboration represents the next phase in the evolution of the QwikAgents\nplatform. Rather than migrating the existing application, Caylent will build a\nnew AWS-native foundation that preserves QwikAgents' core functionality while\nenhancing scalability, performance and security for enterprise deployment and\nfuture product innovation. The engagement is also structured to align with AWS\nfunding programs, with funding support expected from AWS and Caylent.\n\n“This collaboration is an important step in positioning QwikAgents for\nenterprise growth,” said Eric Weisblum, Chief Executive Officer of Silo\nPharma. “By combining our AI platform with Caylent's AWS expertise, we're\ncreating a scalable foundation to accelerate commercialization and future\ninnovation.”\n\nThe AWS-native platform is expected to enhance the scalability, performance\nand security of QwikAgents while accelerating future product development and\nsupporting the platform's long-term commercialization strategy.\n\nAbout Silo Pharma, Inc.\n\nQwikAgents, Silo Pharma's wholly owned artificial intelligence subsidiary, is\na managed AI agent platform that delivers dedicated autonomous agents for\nresearch, content generation, scheduling, and workflow automation — each\nrunning in a persistent environment with proprietary smart-routing across\nmultiple AI models. The subsidiary reflects Silo's strategy to expand into\nhigh-growth technology markets while continuing to advance its core\nbiopharmaceutical pipeline. qwikagents.com\n(https://www.globenewswire.com/Tracker?data=9K6NS4ihN_hVXTaR6lpDPDIj4TmCtZJRVcSGtMw7Ap4CHfXbmUGhbiYMycFQ61z2SxtHgjCaJ_zEx0tVitPYLq3BSAsKdnEKUUXygOnkexCL7JXSBF2mHY7SCuBl3SQxlKq7gR-wel1hMlWchCwgYU9HU9CuzSiAaqQcnadbksKMGm5ENoDbqppWOTvzz5tlDPiC-HpPCBd_v6E2MI6YW5qv_2GPR-ccFocmYJuXskQ=)\n\nSilo Pharma is a diversified developmental-stage biopharmaceutical company\nwith a therapeutic focus on addressing underserved conditions, including\nstress-induced psychiatric disorders, chronic pain, and central nervous system\n(CNS) diseases. The Company’s portfolio includes innovative programs such as\nSPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and\nchronic pain, and a preclinical asset targeting Alzheimer’s disease.\nSilo’s research is conducted in collaboration with leading universities and\nlaboratories. silopharma.com\n(https://www.globenewswire.com/Tracker?data=SNm6qf9BFWv-jBQKKGlrtpSMZWwn-66SI4xErF1TQmGmcYT6HtnIzYfAUfsE50-2PLB2xAZfdHi1TvurO4MVV2NcrxAsAoHWtEUPiq6WEU-Q1U8cflSq3_ssxqgIQok1yfA0fkcg9_1wSaViRbpsm5CWKDH2HBI7k-DvtgA4cBnPJRZcsXMrOUj7aazp1I8yIEsieb0kP-gEajJSzVae8Z13AGPbHoPToIFoBy_xsqKzfKZ4a0cGIzZBQh21ZqiFFM2NHY6nAumu8lNMWR3ErtcO4g9HxBrI4aNpZfsKfnPUeRcvKnJ4hmRn9WQCn7LdnLf7xd_bm8pyKjEjE_LEz1MVIcRZsjkYsDbrOPlkH5G-jraO4NE92iEuo_QJOU5h76WNS6sqoEkQ0mKB2QzI4NCGVqoXygXQmIZTl-vSGZ46p7lrRB6pbgWJBqpTN2_mu3MH__6h0IidZR3lhGqsmj9JXasPdFY-_FPeIEfUPnJSG8EDvyASA3QFmTbu5KRBffjFDWzXfS158impgF3zO9yI-3hkLaxGyWpRVM70bX9sLrxypKOrlezTVugWlDklKQjAC53m8SHQjzlKG8c9D86IR-yyzA7gLN23adkSG_GyR9tsgw9f04qxsR0EqoV_MyNvuj3h61i3bq3EHFHllwBmc-Y5WuWtC_damJ9MYLwwFV4usw23VQkmgUFb0Rnpz3YKwB9kybLQE0m1xEhet-WvkuGTgVbxHO6dFYUiWKP0RyOuRjzoSOyuD_abB368S5VAx5Vo29XQGFAbVMDgXQLPdYfVmOeLjOpmVyAKbweP6n6tUKHngI6T6y65PyXQnOheJHLn9a98MwhBKbm4341GOZdOSYrzH-mBnTqO49BuoetwngXre0TTXUK3d_JDNCCny-IhateG4T4zkfodV_XZ7H6zba9dgkFoFJdQLrVsE4gyqW_fDZngUSANoQyAHr3Y8_9uAt7d2MnHXA9LfJZxpP-ho-d_jzj9oz5frk_DYCX6QWIIkcF_ZN501_ld)\n\nForward Looking Statements\nThis news release contains “forward-looking statements” within the meaning\nof the “safe harbor” provisions of the Private Securities Litigation\nReform Act of 1995. These statements are identified using words “could”,\n“believe”, “anticipate”, “intend”, “estimate”, “expect”,\n“may”, “continue”, “predict”, “potential”, and similar\nexpressions that are intended to identify forward-looking statements. Such\nstatements involve known and unknown risks, uncertainties, and other factors\nthat could cause the actual results of the Company to differ materially from\nthe results expressed or implied by such statements, including statements\nabout changes to anticipated sources of revenues, future economic and\ncompetitive conditions, difficulties in developing the Company’s technology\nplatforms, retaining and expanding the Company’s customer base, fluctuations\nin consumer spending on the Company’s products and other factors.\nAccordingly, although the Company believes that the expectations reflected in\nsuch forward-looking statements are reasonable, there can be no assurance that\nsuch expectations will prove to be correct. The Company disclaims any\nobligations to publicly update or release any revisions to the forward-looking\ninformation contained in this press release, whether as a result of new\ninformation, future events, or otherwise, after the date of this press release\nor to reflect the occurrence of unanticipated events except as required by\nlaw.\n\nContact\n\n(800) 705-0120\ninvestors@silopharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/3b635464-4382-4b8b-8175-39cc32e08050)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-06T12:50:00.149424448Z","server_sent_at_ms":1786020600149},"received_at":"2026-08-06T12:50:00.199Z","source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340312/0/en/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform.html"},"analysis":{"id":"100488","press_release_id":"111485","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Silo Pharma's subsidiary QwikAgents engaged Caylent, an AWS Premier Tier Partner, to build a new AWS-native platform designed to improve scalability and security.\n\nThe collaboration aims to accelerate commercialization and enterprise adoption, with funding support expected from both AWS and Caylent.\n\nCEO Eric Weisblum stated that combining the AI platform with Caylent's expertise creates a scalable foundation for future innovation.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"AI subsidiary partners with AWS specialist to boost enterprise capabilities."},"keyFigures":null,"quotedText":"By combining our AI platform with Caylent's AWS expertise, we're creating a scalable foundation to accelerate commercialization and future innovation.","namedEntities":{"people":[{"name":"Eric Weisblum","role":"Chief Executive Officer"}],"products":["QwikAgents platform","SPC-15","SP-26"],"companies":[{"name":"Silo Pharma","ticker":"SILO"},{"name":"QwikAgents","relationship":"subsidiary"},{"name":"Caylent","relationship":"partner"},{"name":"Amazon Web Services","relationship":"service provider"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Strategic partnership for a subsidiary to enhance platform infrastructure with potential funding support, though it does not impact the core biopharmaceutical pipeline or generate immediate revenue."},"tickerRelevance":{"others":[],"primary":"SILO"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"partnership","sectorWeight":"biotech"}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Silo Pharma's subsidiary QwikAgents engaged Caylent, an AWS Premier Tier Partner, to build a new AWS-native platform designed to improve scalability and security.\n\nThe collaboration aims to accelerate commercialization and enterprise adoption, with funding support expected from both AWS and Caylent.\n\nCEO Eric Weisblum stated that combining the AI platform with Caylent's expertise creates a scalable foundation for future innovation.","key_figures":null,"named_entities":{"people":[{"name":"Eric Weisblum","role":"Chief Executive Officer"}],"products":["QwikAgents platform","SPC-15","SP-26"],"companies":[{"name":"Silo Pharma","ticker":"SILO"},{"name":"QwikAgents","relationship":"subsidiary"},{"name":"Caylent","relationship":"partner"},{"name":"Amazon Web Services","relationship":"service provider"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-06T21:36:00.786Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"partnership","sectorWeight":"biotech"}},"durationMs":81230,"modelName":"glm-4.7"}}